Department of Ophthalmology, Xijing Hospital, Eye Institute of Chinese PLA, Fourth Military Medical University , Xi'an, People's Republic of China.
J Ocul Pharmacol Ther. 2013 Feb;29(1):14-22. doi: 10.1089/jop.2012.0077. Epub 2012 Oct 4.
To evaluate the efficacy of erythropoietin-producing hepatocellular carcinoma receptors B4 (EphB4) knockdown on the development of laser-induced choroidal neovascularization (CNV) in vivo.
We constructed recombinant lentiviral vectors (Lv) Lv-shRNA-EphB4 to specifically knock down the expression of EphB4. The mRNA and protein expression of EphB4 was investigated by real-time reverse transcription-polymerase chain reaction (RT-PCR) and western blot. CNV was induced by laser photocoagulation in C57BL/6 mice. The mice were then randomly assigned to be intravitreally injected with phosphate-buffered saline (PBS), Lv-shRNA-EphB4 recombinant lentivirus, or an unrelated shRNA recombinant lentivirus (pFU LV-shRNA-NC). An uninjected group was used as the control. Fundus fluorescein angiography (FFA), histologic analysis, and choroidal flat mounts analysis were applied to evaluate the inhibition of CNV after an intravitreal injection.
Transfection of Lv-shRNA-EphB4 led to the knockdown of EphB4, and EphB4 mRNA was down-regulated by about 80%. FFA and histologic analysis revealed that the leakage areas and the mean thickness of CNV were much smaller in the Lv-shRNA-EphB4 group than in the PBS-treated, pFU Lv-shRNA-NC group and the non-injection group. Choroidal flat mounts showed significantly less leakage and smaller leakage areas in the Lv-shRNA-EphB4 group than those in other groups.
Knocking down the expression of EphB4 exerts an inhibitory effect on CNV in vivo. It may provide a potential strategy for the treatment of CNV.
评价 EphB4 受体阻断对体内激光诱导脉络膜新生血管(CNV)形成的疗效。
构建重组慢病毒载体(Lv)Lv-shRNA-EphB4 以特异性敲低 EphB4 的表达。通过实时逆转录聚合酶链反应(RT-PCR)和 Western blot 检测 EphB4 的 mRNA 和蛋白表达。采用激光光凝法在 C57BL/6 小鼠中诱导 CNV。然后将小鼠随机分为玻璃体腔内注射磷酸盐缓冲液(PBS)、Lv-shRNA-EphB4 重组慢病毒或无关 shRNA 重组慢病毒(pFU LV-shRNA-NC)。未注射组作为对照。眼底荧光血管造影(FFA)、组织学分析和脉络膜平铺分析用于评估玻璃体腔内注射后 CNV 的抑制情况。
Lv-shRNA-EphB4 的转染导致 EphB4 的敲低,EphB4 mRNA 下调约 80%。FFA 和组织学分析显示,Lv-shRNA-EphB4 组的渗漏面积和 CNV 的平均厚度明显小于 PBS 处理组、pFU Lv-shRNA-NC 组和未注射组。脉络膜平铺显示 Lv-shRNA-EphB4 组的渗漏和渗漏面积明显小于其他组。
阻断 EphB4 的表达对体内 CNV 具有抑制作用。它可能为 CNV 的治疗提供一种潜在的策略。